

1 SUPPLEMENTARY MATERIAL

2 **Anticancer activity of Ophiobolin A, isolated from the Endophytic** 3 **fungus *Bipolaris setariae***

4 Dimple R. Bhatia ^{a*}, Payal Dhar ^a, Varun Mutalik ^b, Sunil Kumar
5 Deshmukh ^b, Shilpa A.Verekar ^b, Dattatraya C. Desai ^c, Rajendra
6 Kshirsagar ^c, Padma Thiagarajan ^d and Veena Agarwal ^a

7 ^aDepartment of Pharmacology, Piramal Enterprises Limited, Mumbai, Maharashtra,
8 India; ^b Department of Natural Products, Piramal Enterprises Limited, Mumbai,
9 Maharashtra, India; ^c Department of Chemistry, Piramal Enterprises Limited, Mumbai,
10 Maharashtra, India; ^d School of Biosciences and technology, VIT University, Vellore,
11 Tamil Nadu, India.

12 *Corresponding author. *Email: dimplebhatia2009@gmail.com

13 The present work describes the anticancer activity of Ophiobolin A isolated from
14 the endophytic fungus *Bipolaris setariae*. Ophiobolin A was isolated using
15 preparative HPLC and its structure was confirmed by HRMS, ¹H NMR, ¹³C
16 NMR, COSY, DEPT, HSQC and HMBC. It inhibited solid and haematological
17 cancer cell proliferation with IC₅₀ of 0.4-4.3 μM. In comparison IC₅₀ against
18 normal cells was 20.9 μM. It was found to inhibit the phosphorylation of S6 (IC₅₀
19 = 1.9 ± 0.2 μM), ERK (IC₅₀ = 0.28 ± 0.02 μM) and RB (IC₅₀ = 1.42 ± 0.1 μM) the
20 effector proteins of PI3K/mTOR, Ras/Raf/ERK and CDK/RB pathways
21 respectively. It induced apoptosis and inhibited cell cycle progression in
22 MDAMB-231 cancer cells with concomitant inhibition of signalling proteins.
23 Thus, this study reveals that anticancer activity of Ophiobolin A is associated
24 with simultaneous inhibition of multiple oncogenic signalling pathways namely
25 PI3K/mTOR, Ras/Raf/ERK and CDK/RB.

26 Keywords: Ophiobolin A, *Bipolaris setariae*, PI3K/mTOR, Ras/ERK, CDK/RB

27 **Experimental**

28 **Fungal identification**

29 The endophytic fungus was isolated from fresh, healthy leaves of *Parthenium*

30 *hysterophorus* Linn. Family Asteraceae (Suryanarayanan et al. 1998) collected in
31 September 2010 from Mumbai, India. The leaves were rinsed twice in sterile distilled
32 water. Surface sterilization was done by immersing the leaves in 70% ethanol for 2 min
33 (two times) followed by rinsing twice in sterile distilled water. The leaves were then
34 cleaved aseptically into small segments (approximately 1 cm in length). The material
35 was placed on 9 cm plates containing potato dextrose agar (PDA) supplemented with
36 chloramphenicol (50 mg/L) to suppress bacterial growth and incubated at 25 ± 1 °C.
37 After several days, hyphae growing from the plant material were transferred to fresh
38 plates with PDA medium, and incubated for 10 days. The culture was periodically
39 checked for purity and subsequently maintained on PDA slants. The culture was
40 assigned the institutional (Piramal enterprises limited) code PM1055406. The fungus
41 was identified as *Bipolaris setariae* using partial sequence analysis of the internal
42 transcribed spacer region (ITS) of rDNA using ITS1 and ITS4 primers (White et al.
43 1990). A nucleotide to nucleotide BLAST (Altschul et al. 1990) query of the gene bank
44 database (<http://www.ncbi.nlm.nih.gov/BLAST>) recovered EF452444.1 *Bipolaris*
45 *setariae* as the closest match to the ITS rDNA of PM1055406 (99%). Evolutionary
46 analyses (Figure S5) were performed using MEGA6 (Tamura et al. 2013). The partial
47 sequence of the ITS of rDNA Culture No. PM1055406 has been deposited with NCBI
48 with the accession number (NCBI No. KP722593).

49 **Isolation and characterisation of Ophiobolin A from *Bipolaris setariae***

50 The separated mycelium from fermented broth of PM1055406 was soaked in methanol
51 for 12 h, filtered and the filtrate was concentrated using rotavapor at 45 °C to yield 3G
52 of crude extract. The crude extract was suspended in 500 mL demineralised water and
53 partitioned with equal volume of ethyl acetate in a separating funnel and the procedure
54 was repeated for three times. The organic layer was concentrated to get 1.2 g of the
55 enriched ethyl acetate extract. The final purification to obtain ophiobolin A was
56 achieved by using preparative HPLC (Column: Waters, X-bridge RP-18, 250 × 10 mm,
57 5 μ). The mobile phase used was an isocratic mixture of acetonitrile and water (1:1) with
58 a flow rate of 5mL/min. The isolated compound was analysed by analytical HPLC for
59 purity (Column: Merck, Lichrosphere, RP-18, 125 × 4 mm; Mobile phase: water and
60 acetonitrile, 98/0, 0/15, 0/20, 98/21, 98/25 (% water/time in min) and was confirmed as
61 Ophiobolin A by different spectroscopic analyses like HRMS, ¹H NMR, ¹³C NMR,

62 HSQC, COSY, DEPT and HMBC. The HRMS data showed the molecular ion peak at
63 m/z 423 for M+Na corresponding to the molecular formula C₂₅H₃₆O₄Na. The
64 spectroscopic data of the isolated compound (Figure S6) was compared with the
65 reported spectral data for Ophiobolin A (Tsuna et al. 2011) and was found to be
66 identical.

67 **Cell lines and antibodies**

68 Cancer cell lines A2780, PC3, MDAMB-231, MCF-7, MM1R, RPMI8226, U266B1
69 and Jurkat were obtained from the American Type Culture Collection (ATCC). Cell
70 lines were cultured in ATCC recommended media supplemented with 10% FBS, 100
71 units/mL penicillin, and 100 mg/mL streptomycin at 37 °C and 5% CO₂. Antibodies
72 directed against pAKT (S473), AKT, pS6 (S235/236), S6, pERK, (Y42/44), ERK,
73 cyclin D1 and actin were obtained from cell signaling technology. Peroxidase labeled
74 anti-rabbit or anti-mouse secondary antibody were obtained from Santacruz
75 biotechnology.

76 **ELISA Assays**

77 All ELISA assays were done in 96 well plates. For pS6 ELISA assay PC3 Cells were
78 seeded at density of 5000 cells per well in RPMI1640 medium containing 10% FBS.
79 After 24 h, cells were serum starved for 16 h. Serum starved cells were treated with
80 Ophiobolin A for 2 h followed by serum stimulation for 30 minutes. At the end of
81 incubation period, cells were fixed and probed with antibodies to pS6 (S235/236). For
82 measurement of pERK levels, MDAMB-231 cells were seeded at a density of 25000
83 cells per well in RPMI 1640 medium containing 10% FBS. After 24 h, medium was
84 replaced with RPMI1640 with 2% FBS and treated with Ophiobolin A for 1 h. At the
85 end of incubation period, cells were fixed and probed with antibodies to pERK
86 (Y42/44). pS6 (S235/236) and pERK (Y42/44) levels were detected using HRP
87 substrate and plates were read at 490 nm using spectramax spectrophotometer
88 (molecular devices, USA). For pRB assay, MDAMB-231 cells were seeded at a density
89 of 20000 cells per well in RPMI1640 medium containing 10% FBS. After 24 h of
90 incubation, cells were treated with Ophiobolin A for 24 h. At the end of the incubation
91 period, cells were fixed and probed with antibodies to pRB (S780). pRB levels were
92 detected with dylight 549 stained secondary antibody and the plates were read on

93 Cellomics Array Scan® VTI HCS Reader. IC₅₀ value for all ELISA assays was
94 determined by plotting percentage cell growth inhibition versus drug concentration
95 using Graph pad Prism software (USA).

96 **Western blot analysis**

97 Cells were seeded at a density of 1X10⁶ and serum starved for 16 h. Serum starved cells
98 were treated with the compound for 2 h or 24 h. Cells were lysed on ice with cell lytic
99 buffer (Sigma C3228) supplemented with protease and phosphatase inhibitors. Proteins
100 were separated on 10-12.5% SDS-PAGE gels and analysed by immunoblotting. Blots
101 were probed with primary antibody for respective proteins at 4 °C for 16 h. Peroxidase
102 labeled anti-rabbit or anti-mouse antibodies (Santacruz) were used as the secondary
103 antibody. Following incubation with secondary antibodies, proteins were detected using
104 super west chemiluminiscence substrate (Pierce). Images were acquired on Bio-Rad gel
105 doc system (USA). Densitometric analysis was done by Image J analysis software
106 (USA). Statistical validation was done with Graph pad prism software. Data were
107 compared by one-way ANOVA followed by Turkey test analysis for multiple
108 comparisons. Differences with respect to control were considered statistically
109 significant at P < 0.05 (n=3).

110 **Cell growth assay**

111 For cell growth effect assay, cells were seeded at a density of 3000 cells per well of
112 appropriate medium containing 10% FBS in a 96 well white plate (Nunclon). After 24 h
113 of incubation in humidified 5% CO₂ incubator at 37 °C, cells were treated with
114 Ophiobolin A for 48 h. At the end of incubation period, the plates were assayed for cell
115 growth inhibition effect using propidium Iodide (PI) for solid tumor cell lines and MTS
116 for haematological cell lines and human peripheral blood mononuclear cells. IC₅₀ value
117 was determined by plotting percentage cell growth inhibition versus drug concentration
118 using Graph pad Prism.

119 **Cell cycle analysis**

120 MDAMB-231 cells were seeded in 6-well plates at a density of 0.5x10⁵ cells. After 16 h
121 of incubation, cells were treated with varying concentrations of Ophiobolin A for 48 h.

122 After treatment, cells were trypsinised, washed and fixed in 70% ethanol in PBS and
123 stored at 4 °C for 24 h. Cells were subsequently suspended in PBS and treated with
124 1µg/µL of RNase A and 1µg/µL of PI in PBS for 45 minutes for staining of DNA. The
125 cell cycle distribution was performed using a BD FACS Calibur flow cytometer and
126 analyzed using Cell Quest software (BD Biosciences, USA).

127 **Caspase-3/7 assay**

128 Caspase-3/7 activity was measured using Caspase-Glo 3/7 assay Kit according to the
129 manufacturer's instructions (Promega, USA). MDAMB-231 cells were seeded at a
130 density of 3000 cells/well in a 96-well plate. After 24 h of incubation, cells were treated
131 with varying concentrations of Ophiobolin A for 48 h. At the end of treatment period,
132 luminescence was measured to calculate caspase-3/7 activity.

133 **Spectral Data**

134 Ophiobolin A: Yellow solid

135 m.p: 167-170 °C.

136 ¹H NMR (500 MHz, CDCl₃): 9.24 (1H, s), 6.83 (1H, dd, *J* = 6.5, 8.5), 5.10 (1H, d, *J* =
137 7.5), 4.47 (1H, ddd, *J* = 8.0, 8.5, 5.0), 3.17 (1H, d, *J* = 10.5), 3.14 (1H, br), 2.93 (1H, d,
138 *J* = 19.0), 2.47 (1H, d, *J* = 17.0), 2.27–1.75 (10H, m), 1.71 (3H, d, *J* = 1.2), 1.62 (3H, d,
139 *J* = 1.2), 1.53 (1H, m), 1.46 (1H, m), 1.24 (3H, s), 1.19 (1H, dd, *J* = 14, 12), 1.14 (3H, d,
140 *J* = 6.5), 0.84 (3H, s). ¹³C NMR (300 MHz, CDCl₃): 216.9, 193.8, 163.3, 142.4, 136.8,
141 125.5, 94.1, 76.5, 71.0, 60.5, 54.8, 49.7, 48.4, 43.1, 42.5, 41.3, 35.1, 34.9, 31.5, 25.8,
142 25.7, 23.5, 18.3, 17.9, 17.7; HRMS (FAB) [M+Na]⁺ calculated for C₂₅H₃₆O₄Na:
143 423.2511, found: 423.2520.

144 **References**

- 145 Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment
146 search tool. *J Mol Biol* 215(3): 403-10.
- 147 Suryanarayanan TS, Kumaresan V, Johnson JA. 1998. Foliar fungal endophytes from
148 two species of the mangrove *Rhizophora*. *Canadian Journal of Microbiology*.
149 44(10): 1003-1006.


150 Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: Molecular
 151 Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. 30: 2725-2729.
 152 Tsuna K, Noguchi N, Nakada M. 2011. Convergent Total Synthesis of (+)-Ophiobolin
 153 A. Angewandte Chemie International Edition 50 (4): 9452-9455.
 154 White TJ, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of
 155 fungal ribosomal RNA genes for phylogenetics in PCR protocols. A guide to
 156 methods and amplifications. (eds.) Innis MA, Gelfand DH, Sninsky JJ and
 157 White TJ; Academic Press San Diego, CA, USA. 315-322.

158 **Tables**


| Sample | Activity at 1 $\mu\text{g/mL}$ | | |
|------------------------------------|--------------------------------|------------------|------------------|
| | % pERK Inhibition | % pS6 Inhibition | % pRB Inhibition |
| Mycelial extract | 71 \pm 6.9 | 66 \pm 7.6 | 60 \pm 7.5 |
| Aq. extract | 10 \pm 1.3 | 5 \pm 0.7 | 12 \pm 1.2 |
| EtOAc extract | 84 \pm 7.1 | 75 \pm 6.8 | 80 \pm 6.9 |
| Pure compound Ophiobolin A | 91 \pm 8.9 | 88 \pm 9.6 | 85 \pm 8.9 |
| PI-103 (0.15 μM) | - | 50 \pm 4.9 | - |
| Sorafenib (0.1 μM) | 50 \pm 8.3 | - | - |
| Staurosporine (0.1 μM) | - | - | 50 \pm 9.7 |

159
 160 Table S1: Bioactivity of isolated fractions at 1 $\mu\text{g/mL}$. PI-103, Sorafenib and
 161 Staurosporin were used as assay standards for pERK, pS6 and pRB respectively at
 162 concentrations mentioned in the parenthesis.
 163

164 **Figures**



166 Figure S1 Effect of Ophiobolin A in pS6, pERK and pRB ELISA assays.




167

168 Figure S2 Cell growth inhibition activity of Ophiobolin A against (a) solid cancer
 169 haematological cancer and (c) Normal cells. IC₅₀ (μM) values are given in parenthesis.


170

171



172

173 Figure S3 Effect of Ophiobolin A on oncogenic proteins in triple negative breast cancer
 174 cell line MDAMB-231 (a) 2 h and (b) 24 h. (c) Densitometry analysis results are shown
 175 as the mean ±SEM of 3 independent experiments. *, P<0.05.




176

177 Figure S4 Effects of Ophiobolin A on cell cycle kinetics (a) 24 h and (b) 48 h. (c)

178 Apoptosis induction in MDAMB-231 cells after 48 h.

179



180


181 Figure S5 Phylogenetic tree based on ITS region sequences for PM1055406 isolate with

182 reference strains. Numbers at the respective nodes are percentage of 1000 bootstrap


183 replicates. Bar indicates genetic distance due to sequence variation.

184

185



186



187

188 Figure S6 ¹³C NMR and ¹H NMR of Ophiobolin A.

189